

Early Toxicity Testing Market by Technique (In Vivo, In Vitro, and In Silico), and End User (Pharmaceuticals Industry, Food Industry, Chemicals Industry, Cosmetics Industry, and Others): Global Opportunity Analysis and Industry Forecast, 2018–2025

<https://marketpublishers.com/r/E9DD97DB70BEN.html>

Date: May 2019

Pages: 210

Price: US\$ 5,370.00 (Single User License)

ID: E9DD97DB70BEN

Abstracts

The early toxicity testing market accounted for \$739 million in 2017, and is expected to reach \$1,301 million by 2025, registering a CAGR of 7.3% from 2018 to 2025.

The degree of threat posed by a chemical substance to the living organism is defined as toxicity. The branch of science that deals with measurement and further analysis of the adverse effects caused by these chemical substances on the body of an organism is called as toxicology. Toxicity testing of chemical substances is performed to select a potential drug candidate for development of newer molecules. Early toxicity is essential as it is the major reason for the failure of potential drug candidates in the later stages of drug development leading to huge financial loss to companies. Therefore, early toxicity testing is carried out at preclinical stages of a drug development process. Moreover, companies perform early toxicity testing to comply with the government standards to market the drug. There are different techniques such as in vivo, in vitro, and in silico that are employed for testing drug to monitor early toxicity associated with them. Different toxicity tests such as ocular toxicity, carcinogenicity, systemic toxicity, and others are performed using these techniques.

Major factors that drive the market growth are surge in the R&D activities and increase in stringency of regulatory authorities concerning public healthcare welfare. In addition, technological advancements in in vitro techniques, rise in adoption of in vitro models in early toxicity testing industry across the globe, and surge in adoption of early toxicity testing further boost the market growth. However, limitations associated with preclinical

testing hamper the market growth. Furthermore, the technological advancements related to early toxicity testing provide lucrative opportunities for the market growth during the forecast period.

This report segments the global early toxicity testing market on the basis of technique, end user, and region to provide a detailed assessment of the market. Based on technique, the market is divided into in vivo, in vitro, and in silico. The market on the basis of in vitro is further divided into in vitro toxicity testing market by assays and in vitro toxicity testing market by toxicity endpoints. The in vitro toxicity testing market by assays is further segmented into enzyme toxicity assays, bacterial toxicity assays, cell-based ELISA & western blots, receptor binding assays, and other assays. The in vitro toxicity testing market by toxicity endpoints is further divided into dermal toxicity, systemic toxicity, carcinogenicity, ocular toxicity, skin sensitization and irritation, neurotoxicity, organ toxicity, and other toxicity endpoints.

On the basis of end user, the market is segmented into pharmaceutical industry, food industry, chemicals industry, cosmetics industry, and other industry. Region wise, the market is studied across different regions such as North America (U.S., Canada and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global early toxicity testing market along with the current trends and future estimations to elucidate the imminent investment pockets.

A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.

In-depth analysis of early toxicity testing techniques such as in vivo, in vitro, and in silico is carried out in the report.

The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Technique

In Vivo

In Vitro

In Vitro Toxicity Testing Market by Assays

Enzyme Toxicity Assays

Bacterial Toxicity Assays

Cell-Based ELISA and Western Blots

Tissue Culture Assays

Receptor Binding Assays

Other Assays

In Vitro Toxicity Testing Market by Toxicity Endpoints

Dermal Toxicity

Systemic Toxicity

Carcinogenicity

Ocular Toxicity

Skin Sensitization and Irritation

Genotoxicity

Neurotoxicity

Organ Toxicity

Other Toxicity Endpoints

In Silico

By End User

Pharmaceuticals Industry

Food Industry

Chemicals Industry

Cosmetics Industry

Other Industries

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Rest of Europe

Asia-Pacific

India

China

Japan

Australia

Rest of Asia-Pacific

LAMEA

Brazil

South Africa

Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Agilent Technologies, Inc.

General Electric Company (GE Healthcare)

Danaher Corporation (Beckman Coulter, Inc.)

Evotec AG (Cyprotex)

Bioanalytical Systems, Inc.

Bruker Corporation

Thermo Fisher Scientific, Inc.

PerkinElmer Inc.

Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.)

Myriad Genetics, Inc. (Myriad RBM.)

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

Randox Toxicology

Geneva Laboratories, Inc.

Advanced Chemistry Development (ACD/Labs)

Contents

CHAPTER 1: INTRODUCTION

- 1.1. Report description
- 1.2. Key benefits for stakeholders
- 1.3. Key market segments
 - 1.3.1. List of key players profiled in the report
- 1.4. Research methodology
 - 1.4.1. Secondary research
 - 1.4.2. Primary research
 - 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. Key findings of the study
- 2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

- 3.1. Market definition and scope
- 3.2. Key findings
 - 3.2.1. Top investment pockets
- 3.3. Top player positioning, 2017
- 3.4. Porter's five forces analysis
- 3.5. Government regulations
- 3.6. Market dynamics
 - 3.6.1. Drivers
 - 3.6.1.1. Surge in R&D activities in healthcare
 - 3.6.1.2. Rise in adoption of in vitro model
 - 3.6.1.3. Increase in stringency of regulatory authorities concerning public healthcare welfare
 - 3.6.1.4. Surge in adoption of early toxicity testing
 - 3.6.2. Restraint
 - 3.6.2.1. Limitations of preclinical testing
 - 3.6.3. Opportunity
 - 3.6.3.1. Technological advancement in the field of early toxicity testing
 - 3.6.4. Impact analysis

CHAPTER 4: EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

4.1. Overview

4.1.1. Market size and forecast

4.2. In Vivo

4.2.1. Key market trends, growth factors, and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market analysis, by country

4.3. In Vitro

4.3.1. Key market trends, growth factors, and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market analysis, by country

4.3.4. In vitro early toxicity testing market, by assay

4.3.4.1. Enzyme toxicity assays

4.3.4.1.1. Market size and forecast

4.3.4.2. Bacterial toxicity assays

4.3.4.2.1. Market size and forecast

4.3.4.3. Cell-based ELISA and western blots

4.3.4.3.1. Market size and forecast

4.3.4.4. Tissue culture assays

4.3.4.4.1. Market size and forecast

4.3.4.5. Receptor binding assays

4.3.4.5.1. Market size and forecast

4.3.4.6. Others

4.3.4.6.1. Market size and forecast

4.3.5. In vitro early toxicity testing market, by toxicity end-point

4.3.5.1. Dermal toxicity

4.3.5.1.1. Market size and forecast

4.3.5.2. Systemic toxicity

4.3.5.2.1. Market size and forecast

4.3.5.3. Carcinogenicity

4.3.5.3.1. Market size and forecast

4.3.5.4. Ocular toxicity

4.3.5.4.1. Market size and forecast

4.3.5.5. Skin sensitization and irritation

4.3.5.5.1. Market size and forecast

4.3.5.6. Genotoxicity

4.3.5.6.1. Market size and forecast

4.3.5.7. Neurotoxicity

- 4.3.5.7.1. Market size and forecast
 - 4.3.5.8. Organ toxicity
 - 4.3.5.8.1. Market size and forecast
 - 4.3.5.9. Others
 - 4.3.5.9.1. Market size and forecast
- 4.4. In silico
 - 4.4.1. Key market trends, growth factors, and opportunities
 - 4.4.2. Market size and forecast, by region
 - 4.4.3. Market analysis, by country

CHAPTER 5: EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

- 5.1. Overview
 - 5.1.1. Market size and forecast
- 5.2. Pharmaceutical industry
 - 5.2.1. Market size and forecast, by region
 - 5.2.2. Market analysis, by country
- 5.3. Food industry
 - 5.3.1. Market size and forecast, by region
 - 5.3.2. Market analysis, by country
- 5.4. Chemicals industry
 - 5.4.1. Market size and forecast, by region
 - 5.4.2. Market analysis, by country
- 5.5. Cosmetic industry
 - 5.5.1. Market size and forecast, by region
 - 5.5.2. Market analysis, by country
- 5.6. Others
 - 5.6.1. Market size and forecast, by region
 - 5.6.2. Market analysis, by country

CHAPTER 6: EARLY TOXICITY TESTING MARKET, BY REGION

- 6.1. Overview
 - 6.1.1. Market size and forecast
- 6.2. North America
 - 6.2.1. Key market trends, growth factors, and opportunities
 - 6.2.2. Market size and forecast, by country
 - 6.2.2.1. U.S.
 - 6.2.2.1.1. U.S. early toxicity testing market, by technique type

- 6.2.2.1.2. U.S. early toxicity testing market, by end user
- 6.2.2.2. Canada
 - 6.2.2.2.1. Canada early toxicity testing market, by technique type
 - 6.2.2.2.2. Canada early toxicity testing market, by end user
- 6.2.2.3. Mexico
 - 6.2.2.3.1. Mexico early toxicity testing market, by technique type
 - 6.2.2.3.2. Mexico early toxicity testing market, by end user
- 6.2.3. Market size and forecast, by technique type
- 6.2.4. Market size and forecast, by end user
- 6.3. Europe
 - 6.3.1. Key market trends, growth factors, and opportunities
 - 6.3.2. Market size and forecast, by country
 - 6.3.2.1. Germany
 - 6.3.2.1.1. Germany early toxicity testing market, by technique type
 - 6.3.2.1.2. Germany early toxicity testing market, by end user
 - 6.3.2.2. France
 - 6.3.2.2.1. France early toxicity testing market, by technique type
 - 6.3.2.2.2. France early toxicity testing market, by end user
 - 6.3.2.3. UK
 - 6.3.2.3.1. UK early toxicity testing market, by technique type
 - 6.3.2.3.2. UK early toxicity testing market, by end user
 - 6.3.2.4. Rest of Europe
 - 6.3.2.4.1. Rest of Europe early toxicity testing market, by technique type
 - 6.3.2.4.2. Rest of Europe early toxicity testing market, by end user
 - 6.3.3. Market size and forecast, by technique type
 - 6.3.4. Market size and forecast, by end user
 - 6.4. Asia-Pacific
 - 6.4.1. Key market trends, growth factors, and opportunities
 - 6.4.2. Market size and forecast, by country
 - 6.4.2.1. Japan
 - 6.4.2.1.1. Japan early toxicity testing market, by technique type
 - 6.4.2.1.2. Japan early toxicity testing market, by end user
 - 6.4.2.2. China
 - 6.4.2.2.1. China early toxicity testing market, by technique type
 - 6.4.2.2.2. China early toxicity testing market, by end user
 - 6.4.2.3. Australia
 - 6.4.2.3.1. Australia early toxicity testing market, by technique type
 - 6.4.2.3.2. Australia early toxicity testing market, by end user
 - 6.4.2.4. India

- 6.4.2.4.1. India early toxicity testing market, by technique type
- 6.4.2.4.2. India early toxicity testing market, by end user
- 6.4.2.5. Rest of Asia-Pacific
 - 6.4.2.5.1. Rest of Asia-Pacific early toxicity testing market, by technique type
 - 6.4.2.5.2. Rest of Asia-Pacific early toxicity testing market, by end user
- 6.4.3. Market size and forecast, by technique type
- 6.4.4. Market size and forecast, by end user
- 6.5. LAMEA
 - 6.5.1. Key market trends, growth factors, and opportunities
 - 6.5.2. Market size and forecast, by country
 - 6.5.2.1. Brazil
 - 6.5.2.1.1. Brazil early toxicity testing market, by technique type
 - 6.5.2.1.2. Brazil early toxicity testing market, by end user
 - 6.5.2.2. South Africa
 - 6.5.2.2.1. South Africa early toxicity testing market, by technique type
 - 6.5.2.2.2. South Africa early toxicity testing market, by end user
 - 6.5.2.3. Rest of LAMEA
 - 6.5.2.3.1. xx early toxicity testing market, by technique type
 - 6.5.2.3.2. rest of LAMEA early toxicity testing market, by end user
 - 6.5.3. Market size and forecast, by technique type
 - 6.5.4. Market size and forecast, by end user

CHAPTER 7: COMPANY PROFILES

7.1. AGILENT TECHNOLOGIES, INC.

- 7.1.1. Company overview
- 7.1.2. Company snapshot
- 7.1.3. Operating business segments
- 7.1.4. Product type Portfolio
- 7.1.5. Business performance

7.2. BIOANALYTICAL SYSTEMS, INC.

- 7.2.1. Company overview
- 7.2.2. Company snapshot
- 7.2.3. Operating business segments
- 7.2.4. Product portfolio
- 7.2.5. Business performance

7.3. BRUKER CORPORATION

- 7.3.1. Company overview
- 7.3.2. Company snapshot

- 7.3.3. Operating business segments
- 7.3.4. Product portfolio
- 7.3.5. Business performance
- 7.4. DANAHER CORPORATION (BECKMAN COULTER, INC.)
 - 7.4.1. Company overview
 - 7.4.2. Company snapshot
 - 7.4.3. Operating business segments
 - 7.4.4. Product type portfolio
 - 7.4.5. Business performance
- 7.5. EVOTEC AG (CYPROTEX)
 - 7.5.1. Company overview
 - 7.5.2. Company snapshot
 - 7.5.3. Operating business segments
 - 7.5.4. Product portfolio
 - 7.5.5. Business performance
- 7.6. ENZO BIOCHEM, INC. (ENZO CLINICAL LABS, INC.)
 - 7.6.1. Company overview
 - 7.6.2. Company snapshot
 - 7.6.3. Operating business segments
 - 7.6.4. Product Portfolio
 - 7.6.5. Business performance
- 7.7. GENERAL ELECTRIC COMPANY (GE HEALTHCARE)
 - 7.7.1. Company overview
 - 7.7.2. Company snapshot
 - 7.7.3. Operating business segments
 - 7.7.4. Product portfolio
 - 7.7.5. Business performance
- 7.8. MYRIAD GENETICS, INC. (MYRIAD RBM.)
 - 7.8.1. Company overview
 - 7.8.2. Company snapshot
 - 7.8.3. Product Portfolio
 - 7.8.4. Business performance
- 7.9. PERKINELMER INC.
 - 7.9.1. Company overview
 - 7.9.2. Company snapshot
 - 7.9.3. Operating business segments
 - 7.9.4. Product Portfolio
 - 7.9.5. Business performance
- 7.10. THERMO FISHER SCIENTIFIC, INC.

- 7.10.1. Company overview
- 7.10.2. Company snapshot
- 7.10.3. Operating business segments
- 7.10.4. Product Portfolio
- 7.10.5. Business performance

List Of Tables

LIST OF TABLES

TABLE 01. GLOBAL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 (\$MILLION)

TABLE 02. GLOBAL IN VIVO EARLY TOXICITY TESTING MARKET, BY REGION, 2017–2025 (\$MILLION)

TABLE 03. GLOBAL IN VITRO EARLY TOXICITY TESTING MARKET, BY REGION, 2017–2025 (\$MILLION)

TABLE 04. IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAYS, 2017–2025 (\$MILLION)

TABLE 05. IN VITRO EARLY TOXICITY TESTING MARKET, BY TOXICITY END-POINT, 2017–2025 (\$MILLION)

TABLE 06. GLOBAL IN SILICO EARLY TOXICITY TESTING MARKET, BY REGION, 2017–2025 (\$MILLION)

TABLE 07. EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 (\$MILLION)

TABLE 08. EARLY TOXICITY TESTING MARKET FOR PHARMACEUTICAL INDUSTRY, BY REGION, 2017–2025 (\$MILLION)

TABLE 09. EARLY TOXICITY TESTING MARKET FOR FOOD INDUSTRY, BY REGION, 2017–2025 (\$MILLION)

TABLE 10. EARLY TOXICITY TESTING MARKET FOR CHEMICAL INDUSTRY, BY REGION, 2017–2025 (\$MILLION)

TABLE 11. EARLY TOXICITY TESTING MARKET FOR COSMETIC INDUSTRY, BY REGION, 2017–2025 (\$MILLION)

TABLE 12. EARLY TOXICITY TESTING MARKET FOR OTHER INDUSTRIES, BY REGION, 2017–2025 (\$MILLION)

TABLE 13. EARLY TOXICITY TESTING MARKET REVENUE, BY REGION, 2017–2025 (\$MILLION)

TABLE 14. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 (\$MILLION)

TABLE 15. U.S. EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 16. U.S. EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 17. CANADA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 18. CANADA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 19. MEXICO EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 20. MEXICO EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 21. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 22. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 23. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 (\$MILLION)

TABLE 24. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 25. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 26. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 27. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 28. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 29. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 30. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 31. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 32. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 33. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 34. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 (\$MILLION)

TABLE 35. JAPAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 36. JAPAN EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 37. CHINA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 38. CHINA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 39. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 40. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 41. INDIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 42. INDIA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 43. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 44. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 45. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 46. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 47. LAMEA EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 (\$MILLION)

TABLE 48. BRAZIL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 49. BRAZIL EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 50. SOUTH AFRICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 51. SOUTH AFRICA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 52. REST OF LAMEA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 53. REST OF LAMEA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 54. LAMEA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 55. LAMEA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 56. AGILENT: COMPANY SNAPSHOT

TABLE 57. AGILENT: OPERATING SEGMENTS

TABLE 58. AGILENT: PRODUCT TYPE PORTFOLIO

TABLE 59. BASI: COMPANY SNAPSHOT

TABLE 60. BASI: OPERATING SEGMENTS

TABLE 61. BASI: PRODUCT PORTFOLIO

TABLE 62. BRUKER: COMPANY SNAPSHOT

TABLE 63. BRUKER: OPERATING SEGMENTS

TABLE 64. BRUKER: PRODUCT PORTFOLIO

TABLE 65. DANAHER: COMPANY SNAPSHOT

| |
|--|
| TABLE 66. DANAHER: OPERATING SEGMENTS |
| TABLE 67. DANAHER: PRODUCT TYPE PORTFOLIO |
| TABLE 68. EVOTEC: COMPANY SNAPSHOT |
| TABLE 69. EVOTEC: OPERATING SEGMENTS |
| TABLE 70. EVOTEC: PRODUCT PORTFOLIO |
| TABLE 71. ENZO: COMPANY SNAPSHOT |
| TABLE 72. ENZO: OPERATING SEGMENTS |
| TABLE 73. ENZO: PRODUCT PORTFOLIO |
| TABLE 74. GE HEALTHCARE: COMPANY SNAPSHOT |
| TABLE 75. GE HEALTHCARE: OPERATING SEGMENTS |
| TABLE 76. GE HEALTHCARE: PRODUCT PORTFOLIO |
| TABLE 77. MYRIAD: COMPANY SNAPSHOT |
| TABLE 78. MYRIAD: PRODUCT PORTFOLIO |
| TABLE 79. PERKINELMER: COMPANY SNAPSHOT |
| TABLE 80. PERKINELMER: OPERATING SEGMENTS |
| TABLE 81. PERKINELMER: PRODUCT PORTFOLIO |
| TABLE 82. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT |
| TABLE 83. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS |
| TABLE 84. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO |

List Of Figures

LIST OF FIGURES

- FIGURE 01. GLOBAL EARLY TOXICITY TESTING MARKET SEGMENTATION
- FIGURE 02. TOP INVESTMENT POCKETS, 2017
- FIGURE 03. TOP PLAYER POSITIONING, 2017
- FIGURE 04. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 06. MODERATE THREAT OF SUBSTITUTION
- FIGURE 07. LOW THREAT OF NEW ENTRANTS
- FIGURE 08. HIGH COMPETITIVE RIVALRY
- FIGURE 09. IMPACT ANALYSES, GLOBAL EARLY TOXICITY TESTING MARKET
- FIGURE 10. COMPARATIVE ANALYSIS OF IN VIVO EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017 & 2025
- FIGURE 11. COMPARATIVE ANALYSIS OF IN VITRO EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017 & 2025
- FIGURE 12. ENZYME TOXICITY ASSAYS MARKET, 2017–2025 (\$MILLION)
- FIGURE 13. BACTERIAL TOXICITY ASSAYS MARKET, 2017–2025 (\$MILLION)
- FIGURE 14. CELL-BASED ELISA & WESTERN BLOTS MARKET, 2017–2025 (\$MILLION)
- FIGURE 15. TISSUE CULTURE ASSAYS MARKET, 2017–2025 (\$MILLION)
- FIGURE 16. RECEPTOR BINDING ASSAYS MARKET, 2017–2025 (\$MILLION)
- FIGURE 17. ASSAYS MARKET FOR OTHERS, 2017–2025 (\$MILLION)
- FIGURE 18. DERMAL TOXICITY MARKET, 2017–2025 (\$MILLION)
- FIGURE 19. SYSTEMIC TOXICITY MARKET, 2017–2025 (\$MILLION)
- FIGURE 20. CARCINOGENICITY MARKET, 2017–2025 (\$MILLION)
- FIGURE 21. OCULAR TOXICITY MARKET, 2017–2025 (\$MILLION)
- FIGURE 22. SKIN SENSITIZATION AND IRRITATION MARKET, 2017–2025 (\$MILLION)
- FIGURE 23. GENOTOXICITY MARKET, 2017–2025 (\$MILLION)
- FIGURE 24. NEUROTOXICITY MARKET, 2017–2025 (\$MILLION)
- FIGURE 25. ORGAN TOXICITY MARKET, 2017–2025 (\$MILLION)
- FIGURE 26. TOXICITY ENDPOINTS MARKET FOR OTHERS, 2017–2025 (\$MILLION)
- FIGURE 27. COMPARATIVE ANALYSIS OF IN SILICO EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017 & 2025
- FIGURE 28. COMPARATIVE ANALYSIS OF EARLY TOXICITY TESTING MARKET FOR PHARMACEUTICAL INDUSTRY, BY COUNTRY, 2017 & 2025
- FIGURE 29. COMPARATIVE ANALYSIS OF EARLY TOXICITY TESTING MARKET

FOR FOOD INDUSTRY, BY COUNTRY, 2017 & 2025

FIGURE 30. COMPARATIVE ANALYSIS OF EARLY TOXICITY TESTING MARKET
FOR CHEMICAL INDUSTRY, BY COUNTRY, 2017 & 2025

FIGURE 31. COMPARATIVE ANALYSIS OF EARLY TOXICITY TESTING MARKET
FOR COSMETIC INDUSTRY, BY COUNTRY, 2017 & 2025

FIGURE 32. COMPARATIVE ANALYSIS OF EARLY TOXICITY TESTING MARKET
FOR OTHER INDUSTRIES, BY COUNTRY, 2017 & 2025

FIGURE 33. AGILENT: REVENUE, 2016–2018 (\$MILLION)

FIGURE 34. AGILENT: REVENUE SHARE BY OPERATING SEGMENT, 2018 (%)

FIGURE 35. AGILENT: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 36. BASI: NET SALES, 2016–2018 (\$MILLION)

FIGURE 37. BASI: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 38. BASI: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 39. BRUKER: NET SALES, 2016–2018 (\$MILLION)

FIGURE 40. BRUKER: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 41. BRUKER: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 42. DANAHER: NET SALES, 2016–2018 (\$MILLION)

FIGURE 43. DANAHER: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 44. DANAHER: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 45. EVOTEC: NET SALES, 2016–2018 (\$MILLION)

FIGURE 46. EVOTEC: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 47. EVOTEC: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 48. ENZO: NET SALES, 2016–2018 (\$MILLION)

FIGURE 49. ENZO: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 50. GE HEALTHCARE: NET SALES, 2016–2018 (\$MILLION)

FIGURE 51. GE HEALTHCARE: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 52. GE HEALTHCARE: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 53. MYRIAD: NET SALES, 2016–2018 (\$MILLION)

FIGURE 54. MYRIAD: REVENUE SHARE, BY SEGMENT, 2018 (%)

FIGURE 55. PERKINELMER: NET SALES, 2016–2018 (\$MILLION)

FIGURE 56. PERKINELMER: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 57. PERKINELMER: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 58. THERMO FISHER SCIENTIFIC: REVENUE, 2016–2018 (\$MILLION)

FIGURE 59. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2018
(%)

FIGURE 60. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2018
(%)

I would like to order

Product name: Early Toxicity Testing Market by Technique (In Vivo, In Vitro, and In Silico), and End User (Pharmaceuticals Industry, Food Industry, Chemicals Industry, Cosmetics Industry, and Others): Global Opportunity Analysis and Industry Forecast, 2018–2025

Product link: <https://marketpublishers.com/r/E9DD97DB70BEN.html>

Price: US\$ 5,370.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E9DD97DB70BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970